Evidence map›Paper›PMID 30200644›Full record

ArticleCells2018

PDGFR and IGF-1R Inhibitors Induce a G2/M Arrest and Subsequent Cell Death in Human Glioblastoma Cell Lines.

Estefania Carrasco-Garcia, Isabel Martinez-Lacaci, Leticia Mayor-López, Elena Tristante, Mar Carballo-Santana, Pilar García-Morales, Maria Paz Ventero Martin, Maria Fuentes-Baile, Álvaro Rodriguez-Lescure, Miguel Saceda

Open access · goldAbstract read
In one paragraph

Article in Cells, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Estefania Carrasco-GarciaInstituto de Biología Molecular y Celular, Universidad Miguel Hernández, 03202 Alicante, Spain. carras.estefania@gmail.com.
Isabel Martinez-LacaciInstituto de Biología Molecular y Celular, Universidad Miguel Hernández, 03202 Alicante, Spain. imlacaci@umh.es.
Leticia Mayor-LópezUnidad AECC de Investigación Traslacional en Cáncer, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain. letiml27@gmail.com.
Elena TristanteUnidad AECC de Investigación Traslacional en Cáncer, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain. elenatristante86@gmail.com.
Mar Carballo-SantanaUnidad AECC de Investigación Traslacional en Cáncer, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain. marcarballosantana@gmail.com.
Pilar García-MoralesInstituto de Biología Molecular y Celular, Universidad Miguel Hernández, 03202 Alicante, Spain. pgarcia@umh.es.
Maria Paz Ventero MartinUnidad de Investigación ISABIAL-FISABIO, Hospital General Universitario de Alicante, 03010 Alicante, Spain. maripazvm@gmail.com.ORCID 0000-0003-1979-0949
Maria Fuentes-BaileUnidad de Investigación ISABIAL-FISABIO, Hospital General Universitario de Alicante, 03010 Alicante, Spain. mariafuentesbaile@gmail.com.
Álvaro Rodriguez-LescureServicio de Oncología del Hospital General Universitario de Elche, 03203 Alicante, Spain. onkopinha@gmail.com.
Miguel SacedaInstituto de Biología Molecular y Celular, Universidad Miguel Hernández, 03202 Alicante, Spain. msaceda@umh.es.
Universitat de Miguel Hernández d'Elx · ESHospital Universitario Virgen de la Arrixaca · ESFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESHospital General Universitario de Elche · ES

Funding

AFECANCER 2017Fundacion de Investigacion Mutua Madrileña 2004Instituto de Salud Carlos III PI012/02025
6 · The paper itself

Abstract

Glioblastomas are highly resistant to radiation and chemotherapy. Currently, there are no effective therapies for this type of tumor. Signaling mechanisms initiated by PDGFR and IGF-1R are important in glioblastoma, and inhibition of the signal transduction pathways initiated by these receptors could be a useful alternative strategy for glioblastoma treatment. We have studied the effects of the PDGFR inhibitor JNJ-10198409 (JNJ) and the IGF-1R inhibitor picropodophyllin (PPP) in glioblastoma cell lines as well as in primary cultures derived from patients affected by this type of tumor. JNJ and PPP treatment blocked PDGFR and IGF-1R signaling respectively and reduced Akt and Erk 1/2 phosphorylation. Both inhibitors diminished cell proliferation, inducing a G2/M block of the cell cycle. Cell death induced by JNJ was caspase-dependent, Annexin-V positive and caused PARP cleavage, especially in T98 cells, suggesting an apoptotic mechanism. However, cell death induced by PPP was not completely inhibited by caspase inhibitors in all cell lines apart from LN-229 cells, indicating a caspase-independent mechanism. Several inhibitors targeted against different cell death pathways could not block this caspase-independent component, which may be a non-programmed necrotic mechanism. Apoptotic arrays performed in T98 and LN-229 cells upon JNJ and PPP treatment revealed that procaspase 3 levels were augmented by both drugs in T98 cells and only by JNJ in LN229-cells. Furthermore, XIAP and survivin levels were much higher in LN-229 cells than in T98 cells, revealing that LN-229 cells are more susceptible to undergo caspase-independent cell death mechanisms. JNJ and PPP combination was more effective than each treatment alone.

Indexed as

cell deathglioblastomaIGF-1RPDFGR

Identifiers

PMID30200644
PMCPMC6162497
OpenAlexW2891713368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.